Introduction
============

Metastatic pancreatic cancer is associated with a poor prognosis. The 5-year overall survival of patients with metastatic pancreatic cancer is 1-2% ([@B1],[@B2]). Recently, based on results from phase III trials, the FOLFIRINOX and gemcitabine (GEM) plus nab-paclitaxel (nab-PTX) regimen has been approved and is used as a standard chemotherapy regimen for metastatic pancreatic cancer ([@B3],[@B4]). In Japan, a phase I/II study of GEM plus nab-PTX as chemotherapy for metastatic pancreatic cancer was performed from 2012 to 2015 to confirm the efficacy and safety. The results showed that GEM plus nab-PTX was associated with promising efficacy, and a response rate of 58.8% and median overall survival of 13.5 months, as well as acceptable toxicity, were observed ([@B5]).

Pancreatic cancer typically originates from the epithelium of the pancreatic duct and causes stenosis of the pancreatic duct and dilation of this duct in the caudal portion of the pancreas. In some patients who develop pancreatic cancer, pancreatitis is also observed before the diagnosis or at the initial stage; however, it typically recovers gradually with symptomatic treatment alone due to the atrophy of the caudal portion of the pancreas. We are unaware of any reports of the late onset of acute pancreatitis after chemotherapy for pancreatic cancer.

In the Japanese study, 2 of 34 (5.9%) total enrolled patients experienced the late onset of pancreatitis after the start of GEM plus nab-PTX. To our knowledge, this is the first report of the late onset of pancreatitis after the start of chemotherapy with GEM plus nab-PTX.

Case Reports
============

Case 1
------

A woman in her 60s was diagnosed with pancreatic head cancer with metastases to the lung and paraaortic lymph nodes. The pathological diagnosis of this patient was invasive ductal carcinoma. Reported complications included hypertension (grade 3), constipation (grade 1) and hyperlipidemia (grade 1). Computed tomography (CT) with intravenous contrast revealed a pancreatic tumor measuring 22 mm in diameter, slight dilation of the pancreatic duct, and no atrophic pancreatic parenchyma ([Fig. 1A and C](#g001){ref-type="fig"}). The patient received five cycles of GEM plus nab-PTX treatment. After five doses, the patient experienced pancreatitis (grade 3) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. In Cycle 2, the patient experienced grade 3 pancreatitis three times, as confirmed by CT ([Fig. 1D-F](#g001){ref-type="fig"}).

![Computed tomography (CT) findings for Case 1. A: Pancreatic head cancer prior to chemotherapy, 22 mm in diameter (arrows). B: Pancreatic head cancer on Cycle 4 Day 21, 19 mm in diameter (best response) (arrows). C: The body and tail of the pancreas prior to chemotherapy. D1-3: The body and tail of the pancreas when Grade 3 pancreatitis (arrowheads) was observed on Cycle 2 Day 10. CT image of ascites (circle). E: The body and tail of the pancreas when Grade 3 pancreatitis (arrowhead) was observed on Cycle 2 Day 24. F: The body and tail of the pancreas when Grade 3 pancreatitis (arrowhead) was observed on Cycle 2 Day 32.](1349-7235-58-2957-g001){#g001}

The dosing regimen, changes in amylase values, C-reactive protein (CRP) levels and the grade of pancreatitis are shown in [Fig. 2](#g002){ref-type="fig"}. Serum amylase and CRP levels were elevated to 3,665 IU/L and 10.8 mg/dL respectively, at 1 month after the start of chemotherapy. CT showed a low density in the pancreas parenchyma with slight dilation of the pancreatic duct and acute necrotic collection (ANC). Nafamostat mesilate was administered to treat the pancreatitis, and the patient was instructed to temporarily fast; fluid replacement of 3 L/day was performed. After the initial onset of pancreatitis was resolved, GEM plus nab-PTX was resumed; however, acute pancreatitis with ANC continued to recur every few weeks, with nafamostat mesilate again administered in response. In Cycle 5, the patient was treated with GEM monotherapy. However, acute pancreatitis with ANC recurred again. Finally, the pancreatitis successfully resolved by one month after the onset of the last episode. Although the patient\'s response to the chemotherapy was stable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, a 13.4% decrease in the sum of the longest diameters of the patient\'s primary lesions was observed ([Fig. 1B](#g001){ref-type="fig"}).

![Changes in amylase values and the grade of pancreatitis for Case 1.](1349-7235-58-2957-g002){#g002}

Case 2
------

A man in his 50s was diagnosed with pancreatic head cancer with metastases to the liver. The patient had obstructive jaundice and had undergone placement of a covered metallic stent before the start of chemotherapy. The pathological diagnosis for the patient was invasive ductal carcinoma. Reported complications included cholestasis (grade 1). CT with intravenous contrast revealed a pancreatic tumor measuring 25 mm in diameter, slight dilation of the pancreatic duct and no atrophic pancreatic parenchyma ([Fig. 3A and C](#g003){ref-type="fig"}).

![Computed tomography (CT) findings for Case 2. A: Pancreatic head cancer prior to chemotherapy, 25 mm in diameter (arrows). B: Pancreatic head cancer on Cycle 8 Day 16, 9 mm in diameter (best response) (arrows). C: The body and tail of the pancreas prior to chemotherapy. D1-4: The body and tail of the pancreas when Grade 2 pancreatitis (arrowheads) was observed on Cycle 3 Day 9. CT scan of ascites (circle). E: The body and tail of the pancreas when Grade 3 pancreatitis with WON (arrowhead) was observed on Cycle 4 Day 15. F: The body and tail of the pancreas when Grade 3 pancreatitis with continuous cyst drainage (arrowhead) was observed on Cycle 9 Day 23.](1349-7235-58-2957-g003){#g003}

The patient received 10 cycles of GEM plus nab-PTX treatment. Treatment was discontinued due to disease progression. After two months, the patient experienced a partial response according to RECIST v1.1 ([Fig. 3B](#g003){ref-type="fig"}), and slight pancreatitis (grade 2) with ANC as assessed by CTCAE version 4.0 in the caudal portion of the pancreas was observed. Pancreatitis was also confirmed by CT ([Fig. 3D1-4](#g003){ref-type="fig"}). Furthermore, CT showed a low-density area in the body of the pancreatic parenchyma as well as surrounding the tail of the pancreas. Gabexate mesilate and fluid replacement of 3 L/day were administered, and the patient was instructed to temporarily fast.

After resuming the administration of GEM plus nab-PTX, the pancreatitis (grade 3) recurred. Although pancrelipase and camostat mesilate were administered, the pancreatitis worsened (grade 4). It became associated with a walled-off necrosis (WON), and the CRP level increased to 29.9 mg/dL in Cycle 4 ([Fig. 3E](#g003){ref-type="fig"}). Endoscopic ultrasound-guided cyst drainage was performed, and the patient\'s infection recovered. GEM plus nab-PTX was resumed and continued for 10 months with continuous cyst drainage. Although the pancreatitis recurred, severe pancreatitis did not develop ([Fig. 3F](#g003){ref-type="fig"}). The dosing regimen, changes in amylase values and CRP levels and the grade of pancreatitis are shown in [Fig. 4](#g004){ref-type="fig"}.

![Changes in amylase values and the grade of pancreatitis for Case 2.](1349-7235-58-2957-g004){#g004}

Discussion
==========

Pancreatitis caused by pancreatic cancer occurs on occasion, with a reported rate of 3% ([@B6]). In general, acute pancreatitis is sometimes induced when the pancreatic duct is stenosed due to pancreatic cancer. However, because of atrophy of the caudal pancreas, most patients do not develop pancreatitis, and pancreatitis usually occurs before the diagnosis or at the initial stage of pancreatic cancer. At later stages, the frequency of pancreatitis decreases due to the progression of pancreatic parenchyma atrophy. In the present two patients, pancreatitis was observed with a late onset, after several courses of chemotherapy. Such patients are very rare and are not typically observed after the start of chemotherapy for pancreatic cancer.

GEM plus nab-PTX was associated with a high response rate (58.8%), and the waterfall plots showed significant tumor shrinkage. Tumor shrinkage rather than drug toxicity, patient predisposition or concomitant medications may have been responsible for the late onset of pancreatitis after starting chemotherapy with GEM plus nab-PTX. Acute pancreatitis may be induced by the alleviation of stenosis of the pancreatic duct associated with tumor shrinkage. In addition, restraint of the atrophy of the pancreatic parenchyma and pancreatic juice stagnation may have also been involved. In these two patients, slight dilation of the pancreatic duct was observed, and the pancreatitis seemed to recur easily. In addition, in Case 2, the presence of a biliary metallic stent seemed to worsen the pancreatitis ([@B7]).

Of note, there have been no reports of similar events of pancreatitis with FOLFIRINOX, which is an equally effective chemotherapy regimen. These pancreatitis cases were therefore thought to be associated with either pancreatic duct obstruction or drug-induced pancreatitis. The detailed reasons for the present findings are unclear due to the limited evidence available at present. There have been no reports of correlations between GEM plus nab-PTX and late onset of pancreatitis. However, there have been reports of improvement in pancreatic parenchyma fibrosis caused by GEM plus nab-PTX ([@B8]), which may improve the pancreatic function and be related to the late onset of pancreatitis.

Conclusion
----------

Two patients experienced the late onset of pancreatitis after the start of GEM plus nab-PTX. As this condition can become serious, due consideration should be given to the risk of pancreatitis as a possible complication with GEM plus nab-PTX.
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